Great inheritance of YHLO iFlash Series, new product being installed
The newly launched YHLO iFlash family member, iFlash 9000, has caught much attention in China’s in vitro diagnostic market. In only a few days after launching, the first iFlash 9000 has been successfully installed and put into operation in a large class A hospital in Jiangsu Province, China.
With up to 600 tests/hour’s throughput, iFlash 9000 is an ideal chemiluminescent immunoassay (CLIA) analyzer for the laboratories and hospitals with large testing volume. And it also supports modular expansion, up to 4 units can be integrated, which can boost the analysis throughput up to 2400 tests/hour. More than 120 parameters are available and assayed as per any combination. Plus, the excellent performance, flexible sample workflow and highly accurate system can greatly improve efficiency, productivity and quality.
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
